Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.50 |
| ▸ | DRD3 | P35462 | 10/20 | 0.50 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.43 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.43 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.43 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773273 | 0.93 | DRD2 (0.49) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL4699085 | 0.80 | DRD2 (0.51) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL4697009 | 0.79 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL1779534 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2ALDH1A1CYP19A1 | |
| SCHEMBL31332598 | 0.77 | DRD2 (0.51) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL16412900 | 0.77 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL6540021 | 0.77 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL29813085 | 0.77 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL4378996 | 0.77 | DRD2 (0.50) | DRD2DRD3ABCC9ABCC8KCNJ11 | |
| SCHEMBL9778875 | 0.76 | GRM5 (0.55) | CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | DRD2 2070/4885DRD3 2692/4885ABCC9 2791/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | DRD2 1674/4885DRD3 1297/4885ABCC9 2239/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | DRD2 4743/4885DRD3 4734/4885ABCC9 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.